PHAXIAM Therapeutics SA (LTS:0QSS)
€ 1.65 0 (0%) Market Cap: 16.39 Mil Enterprise Value: -5.41 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Q3 2022 Erytech Pharma SA Earnings Call Transcript

Nov 22, 2022 / 01:30PM GMT
Release Date Price: €5.9
Operator

Good morning, and thank you for standing by. Welcome to the ERYTECH business update and financial highlights for the third quarter of year 2022. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to turn the conference over to your speaker today, Gil Beyen, CEO of ERYTECH. Please go ahead.

Gil Beyen
ERYTECH Pharma S.A. - CEO

Thank you. Good afternoon. Good morning. Bonjour à tous. Thank you for joining us for our business and financial update call to discuss the business highlights for the third quarter of 2022 and the financials for the first nine months of this year.

We announced our business and financial update yesterday evening, and the press release and webcast presentation can be found on the Investor Relations page of our website.

Turning to slide 2, before starting, as usual, I have to draw your attention to disclaimer to remind you that today's call includes forward-looking statements. And as you know, they all involve risks and uncertainties that could cause actual

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot